Skip to main
KALV
KALV logo

KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharma (KALV) Analyst Ratings

Based on 14 analyst ratings
Strong Buy
Strong Buy 64%
Buy 36%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

KalVista Pharmaceuticals is positioned for a favorable outlook due to its differentiated oral therapy, sebetralstat, for treating acute attacks of hereditary angioedema (HAE) which is expected to provide a significant sales opportunity with a conservative estimate of approximately $400 million in worldwide sales at peak. The convenience and efficacy of sebetralstat, especially in adolescent patients, may lead to increased adoption rates as physicians believe that an oral medication will encourage patients to treat more frequent attacks. The company's strategic focus on launching a novel treatment in a stabilized HAE market, combined with encouraging recent clinical data and a high probability of regulatory approval, underscores a positive trajectory for KalVista Pharmaceuticals.

Bears say

KalVista Pharmaceuticals Inc. reported a significant net loss of $44.3 million, translating to a loss of $0.92 per share for the third quarter ended January 31, 2025, highlighting ongoing financial struggles. The company faces considerable risks, including the potential failure of its lead product, sebetralstat, which could hamper future growth prospects, as the existing pipeline lacks alternative candidates to support revenue generation. Additionally, the uncertainty surrounding regulatory approval and market acceptance of sebetralstat, particularly for critical applications such as laryngeal attacks, further exacerbates the financial risks associated with the company’s operations and growth trajectory.

KalVista Pharma (KALV) has been analyzed by 14 analysts, with a consensus rating of Strong Buy. 64% of analysts recommend a Strong Buy, 36% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of KalVista Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About KalVista Pharma (KALV) Forecast

Analysts have given KalVista Pharma (KALV) a Strong Buy based on their latest research and market trends.

According to 14 analysts, KalVista Pharma (KALV) has a Strong Buy consensus rating as of Jul 28, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

KalVista Pharma (KALV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.